Inhibikase Therapeutics, Inc.
IKT · XNASCIK 1750149fmd_08SWPG037SQCG6587MBFD12A5HManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 1 | 3 | 0 | 0 | 0 | – |
| Net interest income | – | (0) | 0 | 1 | 1 | 4 |
| Research and development | 1 | 11 | 12 | 14 | 17 | 30 |
| Selling, general and administrative | 3 | 7 | 6 | 7 | 11 | 24 |
| Operating income | (3) | (15) | (18) | (20) | (29) | (52) |
| Interest expense | 0 | 0 | – | – | – | – |
| Income before taxes | – | – | – | – | (0) | (0) |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (0) | (0) |
| Net income | (3) | (15) | (18) | (19) | (28) | (48) |